TransCode Therapeutics, Inc. (RNAZ)
1.88
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 15:06
TransCode Therapeutics Total Liabilities (Quarterly) : 12.65M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.65M |
| March 31, 2026 | 12.64M |
| December 31, 2025 | 10.52M |
| September 30, 2025 | 3.801M |
| June 30, 2025 | 2.119M |
| March 31, 2025 | 2.902M |
| December 31, 2024 | 9.313M |
| September 30, 2024 | 2.284M |
| June 30, 2024 | 3.502M |
| March 31, 2024 | 2.706M |
| December 31, 2023 | 3.529M |
| September 30, 2023 | 5.788M |
| June 30, 2023 | 3.789M |
| March 31, 2023 | 5.827M |
| Date | Value |
|---|---|
| December 31, 2022 | 4.347M |
| September 30, 2022 | 3.771M |
| June 30, 2022 | 1.727M |
| March 31, 2022 | 1.849M |
| December 31, 2021 | 2.534M |
| September 30, 2021 | 2.205M |
| June 30, 2021 | 6.558M |
| March 31, 2021 | 8.884M |
| December 31, 2020 | 4.464M |
| September 30, 2020 | 3.792M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 1.314M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.641M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 151.01M |
| Shareholders Equity (Quarterly) | 138.36M |
| Debt to Equity Ratio | 0.0047 |
| Current Ratio | 1.971 |
| Net Debt Paydown Yield | -2.08% |